| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?
|
Callander, Natalie Scott
|
|
|
11 |
6 |
p. e392-e393
|
article
|
| 2 |
Correction to Lancet Haematol 2024; 11: e27–37
|
|
|
|
11 |
6 |
p. e399
|
article
|
| 3 |
Correction to Lancet Haematol 2018; 5: e232
|
|
|
|
11 |
6 |
p. e399
|
article
|
| 4 |
Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT
|
Pagliuca, Simona
|
|
|
11 |
6 |
p. e448-e458
|
article
|
| 5 |
Eltrombopag–cyclosporin A in treating severe aplastic anaemia
|
Sathiamoorthy, Krishna sai
|
|
|
11 |
6 |
p. e397
|
article
|
| 6 |
Eltrombopag–cyclosporin A in treating severe aplastic anaemia – Authors' reply
|
Scheinberg, Phillip
|
|
|
11 |
6 |
p. e398
|
article
|
| 7 |
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study
|
Craig, Timothy J
|
|
|
11 |
6 |
p. e436-e447
|
article
|
| 8 |
Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial
|
Aygun, Banu
|
|
|
11 |
6 |
p. e425-e435
|
article
|
| 9 |
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management
|
Rejeski, Kai
|
|
|
11 |
6 |
p. e459-e470
|
article
|
| 10 |
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial
|
O'Donnell, Elizabeth
|
|
|
11 |
6 |
p. e415-e424
|
article
|
| 11 |
Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa
|
Galadanci, Najibah A
|
|
|
11 |
6 |
p. e393-e395
|
article
|
| 12 |
Long term strategies for individuals with sickle cell disease
|
The Lancet Haematology,
|
|
|
11 |
6 |
p. e391
|
article
|
| 13 |
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study
|
Dupuis, Jehan
|
|
|
11 |
6 |
p. e406-e414
|
article
|
| 14 |
Step out of the shadows: a call for action for rare diseases
|
Granata, Francesca
|
|
|
11 |
6 |
p. e403
|
article
|
| 15 |
Striking the right balance
|
Coltoff, Alexander
|
|
|
11 |
6 |
p. e402
|
article
|
| 16 |
50th Annual Meeting of the EBMT
|
del Pozo Martín, Yaiza
|
|
|
11 |
6 |
p. e400-e401
|
article
|
| 17 |
The effects of upward revision of haemoglobin thresholds for anaemia in blood donations
|
Sato, Tomohiko
|
|
|
11 |
6 |
p. e396-e397
|
article
|
| 18 |
The effects of upward revision of haemoglobin thresholds for anaemia in blood donations – Authors' reply
|
Fielding, Katherine L
|
|
|
11 |
6 |
p. e397
|
article
|
| 19 |
Trends, opportunities, and challenges of clinical trials for haematological diseases in China
|
Qi, Jianwei
|
|
|
11 |
6 |
p. e404-e405
|
article
|
Journal description